SCHEMBL5440445

SCHEMBL5440445

CC(NC(=O)c1cc2ccccc2n(-c2cccc(C(F)(F)F)c2)c1=O)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PLA2G10 O15496 1/20 0.51
POLB P06746 1/20 0.48
GPR139 Q6DWJ6 1/20 0.47
CNR1 P21554 2/20 0.47
CNR2 P34972 2/20 0.47
PTGER4 P35408 4/20 0.46
PTGDR Q13258 2/20 0.46
ATM Q13315 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
ACACB O00763 2/20 0.44
NOTUM Q6P988 1/20 0.43
PPARG P37231 1/20 0.42
KCNQ3 O43525 1/20 0.42
KCNQ2 O43526 1/20 0.42
LIPG Q9Y5X9 1/20 0.42
PHGDH O43175 1/20 0.41
PDE2A O00408 1/20 0.41
RAB9A P51151 1/20 0.41
GSR P00390 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5441769 0.93 PLA2G10 (0.48) PLA2G10POLBGPR139CNR1CNR2
SCHEMBL5756526 0.84 ELANE (0.57) POLBGPR139CNR1CNR2PTGER4
SCHEMBL5756492 0.84 ELANE (0.57) POLBGPR139CNR1CNR2PTGER4
SCHEMBL561192 0.83 CNR1 (0.50) GPR139CNR1CNR2PTGER4PTGDR
SCHEMBL31490266 0.83 CNR1 (0.50) GPR139CNR1CNR2PTGER4PTGDR
SCHEMBL11894963 0.81 CNR1 (0.51) GPR139CNR1CNR2PTGER4PTGDR
SCHEMBL5445143 0.81 PLA2G10 (0.56) PLA2G10NOTUMPPARGGSR
SCHEMBL5443573 0.79 PLA2G10 (0.52) PLA2G10CNR1CNR2L3MBTL1PPARG
SCHEMBL5438329 0.78 ELANE (0.59) PLA2G10POLBPPARG
SCHEMBL5440472 0.77 DDT (0.56) PLA2G10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070010551-A1 Quinoline derivatives as neutrophil elastase inhibitors and their use ASTRAZENECA AB (SE) 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010551-A1 Quinoline derivatives as neutrophil elastase inhibitors and their use SERPINB1, ELANE, MPO PLA2G10 1148/4885POLB 698/4885GPR139 1896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.